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A potassium loading study was performed in acutely nephrectomized rats to determine the
extrarenal effects of diuretics on potassium tolerance. Four diuretics were evaluated: hydro-
chlorthiazide, furosemide, bumetanide, and spironolactone. Following an intravenous potas-
sium load (0.17 mEq/100 g over one hour), plasma potassium concentration rose by 2.69 4 0.26
to 3.67 i 0.20 mEq/L in all groups. There was no difference in the observed increment in
plasma potassium concentration between animals receiving diuretics and control animals.
These results demonstrate that, at the doses used, diuretics do not impair extrarenal potassium
disposal in the rat.
INTRODUCTION
It has become increasingly clear that extrarenal mechanisms play an important
role in overall potassium homeostasis, particularly in acute potassium tolerance [1].
It has been shown in humans [2-4], in dogs [2], and in rats [5] that less than 50 per-
cent of an acute exogenous K load is excreted by the kidney in the first four to six
hours following administration. The greater part of the remainder of the K load is
disposed of by extrarenal mechanisms, thus defending the extracellular fluid from
life-threatening hyperkalemia. The major factors which regulate this extrarenal
potassium disposal include acid-base balance, actions of hormones including insu-
lin, catecholamines, mineralocorticoids, and glucocorticoids and drugs.
While diuretics are among the most commonly used pharmacologic agents in clini-
cal medicine, there has been little emphasis on the role of diuretics in ion transport
outside the kidney. It appears, however, that the actions of diuretics may not be
limited to the renal epithelium. For example, furosemide has been shown to cause a
prompt increase in venous capacitance which precedes its diuretic effect [6]. More
recently, furosemide has been used in defining an ion cotransport mechanism which
exists in several cell system such as the loop of Henle [7,8], as well as extrarenal cell
systems such as avian [9,10] and human red blood cells [11-13]. This system, which
transports Na, K, and Cl into the cell, is inhibited by furosemide. The ability of
furosemide and other aminobenzoic acid derivatives, such as bumetanide, to act as
inhibitors ofthe transport system appears to be directly correlated with their diuretic
potency [9]. If this cotransport system has major significance in the whole animal,
especially in muscle and liver cells where potassium is stored, then extrarenal potas-
sium tolerance could be influenced by administration of loop diuretics.
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All rights of reproduction in any form reserved.Further evidence for an extrarenal effect of furosemide as well as thiazides is ob-
vious from their use as antihypertensive agents. The blood-pressure lowering action
of both of these drugs has been shown to persist even after their diuretic effect has
ceased [14-16]. Data suggesting that thiazides may also have an effect on extrarenal
potassium tolerance is found in a recent report demonstrating thiazide-induced cor-
rection of hyperkalemia without evidence for increased potassium losses [17].
Aldosterone has been shown to have an effect on extrarenal potassium disposal
[1,21]. Mineralocorticoids appear to enhance K uptake by extrarenal tissues [18,19],
and extrarenal K tolerance is diminished in their absence [20,211. One might,
therefore, expect then that mineralocorticoid inhibition with an agent such as
spironolactone would impair extrarenal potassium tolerance.
We undertook this study to examine the effects of diuretics from three chemical
families on extrarenal potassium disposal. The establishment of an extrarenal effect
ofdiuretics on potassium transport would enhance our knowledge ofthe mechanism
ofaction ofthese agents. Furthermore, the demonstration of an improvement in ex-
trarenal potassium tolerance with certain diuretics would have important clinical im-
plications in the treatment of hyperkalemia in patients with renal failure.
METHODS
In order to evaluate the effects of diuretics on extrarenal potassium tolerance, a
potassium loading study was performed in male Sprague Dawley rats (Charles
River, Boston, MA) following acute bilateral nephrectomy. Three classes of
diuretics were evaluated: thiazides, loop diuretics (furosemide and bumetanide), and
aldosterone antagonists. All rats weighed 225-265 grams and were divided into the
following four groups:
Group I-Hydrochlorthiazide Group
Six rats received an intravenous dose of hydrochlorthiazide (5 mg/Kg) 30
minutes prior to the infusion of KCI (Fig. 1). The diuretic was dissolved in a
32 percent ethanol solution and delivered in a volume of 0.5 ml. Six rats
receiving an equivalent volume of the ethanol solution alone, prior to KCI,
served as controls for this group.
Group II-Furosemide Group
Six rats received an intravenous dose of furosemide (20 mg/Kg) 30 minutes
prior to the infusion of KCI (Fig. 1). Six rats receiving an equivalent volume
of the aqueous vehicle alone, prior to KCI, were studied as controls.
Group III-Bumetanide Group
Three rats received bumetanide (0.25 mg/Kg) intravenously 30 minutes prior
to KCI infusion (Fig. 1). The bumetanide was dissolved in a 10 percent
ethanol solution. Three rats receiving an intravenous dose of the ethanol
vehicle alone served as controls.
Group IV-Spironolactone Group
Six rats received spironolactone (10 mg/Kg) subcutaneously 24-30 hours
prior to study and again 210 minutes prior to KCI loading (Fig. 1). The
spironolactone was dissolved in DMSO. Six rats receiving an equivalent
volume of DMSO alone served as Group IV controls.
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FIG. 1. Experimental protocol followed for potassium loading study. Diuretics were administered in-
travenously except for spironolactone, which was injected subcutaneously.
During each KCI loading study, a diuretic-treated rat was studied concomitantly
with an untreated rat to control for time-related changes in each parameter exam-
ined.
In order to maintain similar potassium balance prior to study, all animals were
maintained on 15 grams of Standard Purina Rat Chow (Na and K content equal to
2.5 and 4.0 mEq/day, respectively) for four to seven days before study. Each rat
consumed the entire 15 grams of chow daily. All animals were allowed free access to
water.
Diuretic Dose
In a separatestudy, thediureticeffectiveness ofthedoses used for hydrochlorthia-
zide and furosemide were evaluated. Sprague Dawley rats (200-250 g) underwent a
clearance study under Inactin anesthesia and following catheterization of blood
vessels, urine was collected at thirty-minute intervals before and after administration
ofhydrochlorthiazide (5 mg/kg) or furosemide (20 mg/kg). Thedose ofdiuretic was
considered effective ifit resulted in an increase in both urine volume and sodium ex-
cretion.
The renal effect of bumetanide was not evaluated since it is ineffective as a
diuretic in the rat [22]. Although it has been suggested that inhibition ofthe Na-K-Cl
cotransport system correlates with naturetic potency [9], this fact has not yet been
firmly established. We wished to evaluate the extrarenal effect of bumetanide since
it is a more specific inhibitor ofthe cotransport mechanism than furosemide in avian
erythrocytes [9]. As it is forty times more potent than furosemide on a molar basis
[23], a dose of 0.25 mg/kg was chosen, which is approximately 2.5 times the in-
travenous dose effective at producing a diuresis on dogs [24]. Spironolactone was
administered 24 hours and again approximately two hours before KCI loading, as
previous data have shown that it takes eight to ten hours to achieve maximum
aldosterone blockade in the rat and that binding at the receptor site may persist after
plasma levels decline [25]. Effective blockade of aldosterone action in rat kidney
with spironolactone occurs at a ratio of400-800: 1 spironolactone: aldosterone [26].
A dose of 10 mg/kg was chosen since this is two to seven times the diuretic dose used
in man, and should block physiologic aldosterone production rates in the rat.
Potassium Loading Study (Fig. 1)
Rats were fasted the evening before study. On the morning of study, the animals
were anesthetized with Inactin (Promonta, Hamburg, Germany), 12 mg/ 100 g body
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means of a warming board. A tracheostomy was performed and an external jugular
vein and carotid artery were cannulated to permit infusion of test substances and
withdrawal of blood samples, respectively. Bilateral nephrectomy was then per-
formed through a midline abdominal incision with care taken not to disturb the
blood supply of the adrenal glands. After surgery, all animals received a 1 percent
body weight bolus of0.15 M NaCl over 20 minutes followed by a maintenance infu-
sion of 0.15 M NaCl at 0.35 ml/100 g body weight/hour thereafter. A Harvard
pump (Harvard Apparatus, Millis, MA) was used to deliver all infusions.
Following 60 minutes of equilibration (T = - 105 to T = -45, Fig. 1), two
carotid artery blood samples were obtained 15 minutes apart (T = -45 and - 30)
for analysis ofplasma Na and K concentrations prior to diuretic administration. Im-
mediately following the second blood sample, an intravenous dose ofa diuretic or its
vehicle, in a volume of0.5 ml, was given in Groups I-III. Group IV rats received the
second dose of spironolactone or its vehicle at T = -210 minutes. Two more
carotid blood samples (Pi and P2) were obtained 15 minutes apart (T = -15 and 0)
for analysis of baseline plasma Na and K concentrations after diuretic administra-
tion and before KC1 infusion. At T = 0 minutes, the saline infusion was replaced
with an infusion of0.5 M KCI administered at 0.35 ml/100 gm body weight/hour to
deliver a K load of 0.17 mEq of potassium per 100 gm body weight over one hour.
Four carotid blood samples (P3-P6) were obtained at 15-minute intervals during the
KCI infusion for measurement of plasma sodium and potassium concentrations.
Blood pressure, measured with a mercury manometer attached to the carotid artery
catheter, was taken at thirty-minute intervals before and after KCl loading.
Hematocrit was measured on every blood sample as an approximate guide to
changes in intravascular volume.
Data Analysis
Sodium and potassium concentrations were measured with a flame photometer
(Instrumentation Laboratories, Lexington, MA) using an internal lithium standard.
The rise in plasma potassium concentration at the end of each time interval during
KCI loading was used as an index of potassium tolerance. This APk was calculated
by subtracting the baseline from the experimental plasma potassium concentration
during each time period. Changes in plasma Na at these times as well as changes in
hematocrit and blood pressure during each period were calculated and compared for
all groups. Results of each experimental group were then compared with results
from the concomitantly studied control group and analyzed by the Student t-test.
All values are given as the mean i the standard error of the mean.
RESULTS
Diuretic Dose
The dose of thiazide chosen, 5 mg/kg, produced a three- to sixfold increase in
urine flow rate and a 12- to 14-fold increase in sodium excretion ninety minutes after
intravenous administration in two test rats. Similarly, furosemide, at 10 mg/kg, in-
duced a three- to fourfold increase in flow rate and a greater than fourfold rise in
sodium excretion 60 minutes after injection into two test rats, verifying the diuretic
potency of the doses used.
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Potassium Loading Study
Baseline plasma potassium values were similar to those obtained during equilibra-
tion in each group indicating that baseline plasma potassium concentration was
unaltered by diuretic administration. Values for mean baseline plasma potassium
concentration were similar between groups ranging from 4.57 + 0.15 to 5.21 + 0.13
mEq/L. Of note was the datum that the baseline plasma potassium level in animals
receiving spironolactone (5.12 + 0.11 mEq/L) was similar to the value obtained in
the concomitantly studied control group (4.83 0.19 mEq/L).
The effects of KCI loading on the rise in plasma potassium concentration (APk) is
shown in Fig. 2. The maximal APk after one hour of KCI was similar in all groups
and ranged between 2.69 0.26 and 3.67
- 0.20 mEq/L. Specifically, theincrement
in plasma potassium concentration in rats receiving diuretics was similar during each
time period to the value obtained in the concomitantly studied control group.
Plasma sodium concentration ranged between 137 + 3 to 143 ± 1 mEq/L during
the baseline period. There were no significant differences in plasma sodium concen-
tration between groups or within any given group during study. Mean blood
pressures during equilibration was similar in all groups ranging from 100 + 5 to 112
i 6 mm Hg. Blood pressure remained stable throughout the study in all animals ex-
cept for a slight, transient decrease in Group I rats soon after the administration of
hydrochlorthiazide (decreased to 87 a 9 mm Hg) or its ethanol vehicle (decreased
to 94 + 12 mm Hg). In these animals, blood pressure returned to baseline levels dur-
ing K loading. Mean hematocrit values prior to KCI loading were similar in all
groups (48 i 1 to 52 + 0.3 percent) and remained unchanged throughout the study.
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FIG. 2. Increment in plasma potassium concentration during 60 minutes of KCI infusion in Groups
I-IV. Each diuretic-treated rat was studied simultaneously with an untreated control rat from that group.
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The purpose of this study was to examine the effects of diuretics on extrarenal
potassium disposal. The results indicate that furosemide, bumetanide, hydrochlo-
rothiazide, and spironolactone, at the doses employed, do not significantly alter the
ability of the acutely nephrectomized rat to tolerate a potassium load. The in-
crements in plasma potassium concentration following intravenous KCl administra-
tion were not significantly different in animals given diuretics as compared to con-
trols given no diuretics.
The finding that neither furosemide nor bumetamide in the doses used influenced
extrarenal potassium tolerance has important implications concerning mechanisms
of extrarenal potassium disposal. Potassium can be transported into the cell via the
classic Na-K ATPase pathway in which sodium is extruded from cells as potassium
enters or via the newly described system of Na-K-Cl cotransport. In this latter
pathway, which is stimulated by 3-adrenergic agents, and inhibited by loop diuretics
in the aminobenzoic acid family, sodium, potassium, and chloride are transported
into cells by a cotransport mechanism [7,9,12,13,27-29]. While the system has been
described in the loop of Henle [7,8] as well as in avian and human erythrocytes
[9-13], its physiologic significance in other cells of the body is unknown. Liver and
muscle are the most important organs of extrarenal potassium disposal during K
loading. If the cotransport system was an important mechanism of potassium up-
take in these organs, one might expect an impairment in potassium tolerance follow-
ing blockade of this pathway with furosemide. As is evident in Fig. 2, potassium
tolerance in furosemide-treated rats was similar to that of control animals. These
results suggest that the cotransport mechanism of potassium uptake may not be a
major regulator of in vivo extrarenal potassium homeostasis in the rat. Alternatively,
it is possible that the concentration of free furosemide in the current experiment was
too low to be effective. While the dose of furosemide used was effective in blocking
sodium chloride absorption in the loop of Henle, concentrations of the unbound
drug in this nephron segment should be considerably higher than circulating levels
because the diuretic is secreted and concentrated in the tubular lumen [30]. Since
furosemide is 95 percent protein-bound [31], it is possible that the amount of free
circulating diuretic in the current experiment was less than the10- - 10-3M concen-
tration necessary to inhibit the cotransport mechanism [9]. Furthermore, circulating
epinephrine levels are known to be extremely high in nephrectomized, K-loaded rats
[21]. Failure to observe an effect of furosemide on extrarenal potassium tolerance in
the present study may be attributable to maximal 3-adrenergic stimulation of
potassium uptake, not reversible with the doses of furosemide used.
It is less surprising that bumetanide failed to alter extrarenal potassium disposal.
Our results support previous findings suggesting that the ability of diuretics, in the
aminobenzoic acid class, to inhibit the cotransport mechanism is related to
natriuretic potency [9]. Since bumetanide is not an effective diuretic in the rat [22],
then it is likely that it has no extrarenal effect as results from the present study in-
dicate. However, the current data do not exclude the possibility that an impairment
in potassium tolerance may be seen at higher doses of the drug.
It has recently been suggested that the hypokalemia associated with thiazide ad-
ministration may reflect redistribution of potassium rather than an absolute loss of
total body potassium [32]. Furthermore, thiazides have been reported to correct
hyperkalemia in certain patients with a concomitant increase in urinary potassium
excretion [17], thus supporting the redistribution hypothesis. If the hypokalemic ef-
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fect ofthiazides were caused, at least in part, by cellular redistribution ofpotassium,
one would expect that extrarenal potassium tolerance would be enhanced in the
presence of this diuretic. In the current study, an improvement in extrarenal
potassium tolerance was not observed in thiazide-treated animals. Although the
thiazide dose chosen was effective in the distal nephron where the free drug is con-
centrated, it is again possible that circulating levels of the free drug were not suffi-
ciently high to observe an effect on extrarenal potassiumdisposal. The extrarenal ac-
tion of thiazides observed in other studies has been reported with long-term use of
the diuretic. It is possible that chronic administration ofthiazide is necessary before
an effect on extrarenal potassium tolerance is observed.
Aldosterone administration can enhance extrarenal potassium disposal [18,19]
and aldosterone insufficiency is associated with an impairment in extrarenal
potassium tolerance [21]. It is therefore surprising that extrarenal potassium
tolerance was unaffected by spironolactone administration in the current study. The
dose chosen has been shown to block endogenous aldosterone action in rat colon
[33] as well as the action ofexogenously administered aldosterone in rat kidney [26].
It is possible, however, that this dose of spironolactone provided insufficient
mineralocorticoid blockade for the elevated levels of aldosterone produced with
potassium loading. It is also possible that the time course of spironolactone injec-
tions provided insufficient aldosterone blockade at the time of K loading. Since
maximum spironolactone effect in the rat is observed eight to ten hours after ad-
ministration ofthe drug and since the hormone may persist at the receptor sites after
plasma levels decline [25], injection ofthe hormone 24 and two hours before KCI in-
fusion was thought to produce adequate mineralocorticoid blockade. If, however,
the biologic effect ofthe first spironolactone injection had declined before the effect
of the second dose became maximal, then insufficient aldosterone inhibition would
occur and potassium tolerance would remain normal. More prolonged administra-
tion of spironolactone was avoided in this study to avoid potassium retention prior
to study.
In summary, the current results demonstrate that, within the limits of the ex-
perimental design of this study, diuretics do not appear to modify extrarenal
potassium tolerance in the rat at the doses used. These data do not exclude the
possibility that an extrarenal effect on potassium might be observed at higher doses
ofthe drugs. However since the doses ofdiuretic chosen are similar to or higher than
the doses employed to produce a diuresis in clinical settings, the evidence does sug-
gest that diuretics would be ineffective in improving acute potassium tolerance in pa-
tients with significant renal failure.
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